TRAIL (C92B9) Rabbit Monoclonal Antibody (BSA and Azide Free)#48318,Cell Signaling Technology (CST),48318

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (6,8,10,11) and DcR2 (TRAIL-R4, TRUNDD) (12,13) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (14). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (15,16).Wiley, S.R. et al. (1995)Immunity3, 673-82.Pitti, R.M. et al. (1996)J Biol Chem271, 12687-90.Almasan, A. and Ashkenazi, A.Cytokine Growth Factor Rev14, 337-48.Pan, G. et al. (1997)Science276, 111-3.Walczak, H. et al. (1997)EMBO J16, 5386-97.MacFarlane, M. et al. (1997)J Biol Chem272, 25417-20.Chaudhary, P.M. et al. (1997)Immunity7, 821-30.Schneider, P. et al. (1997)FEBS Lett416, 329-34.Shetty, S. et al. (2002)Apoptosis7, 413-20.Sheridan, J.P. et al. (1997)Science277, 818-21.Degli-Esposti, M.A. et al. (1997)J Exp Med186, 1165-70.Pan, G. et al. (1998)FEBS Lett424, 41-5.Marsters, S.A. et al. (1997)Curr Biol7, 1003-6.Kelley, S.K. et al. (2001)J Pharmacol Exp Ther299, 31-8.Walczak, H. et al. (1999)Nat Med5, 157-63.Ashkenazi, A. et al. (1999)J Clin Invest104, 155-62.Alternate NamesApo-2 ligand; Apo-2L; APO2L; CD253; chemokine tumor necrosis factor ligand superfamily member 10; Protein TRAIL; TL2; TNF superfamily member 10; TNF-related apoptosis inducing ligand TRAIL; TNF-related apoptosis-inducing ligand; TNF10; TNFSF10; TNLG6A; TRAIL; tumor necrosis factor (ligand) family, member 10; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor apoptosis-inducing ligand splice variant delta; tumor necrosis factor ligand 6A; Tumor necrosis factor ligand superfamily member 10; tumor necrosis factor superfamily member 10

Apo-2 ligand; Apo-2L; APO2L; CD253; chemokine tumor necrosis factor ligand superfamily member 10; Protein TRAIL; TL2; TNF superfamily member 10; TNF-related apoptosis inducing ligand TRAIL; TNF-related apoptosis-inducing ligand; TNF10; TNFSF10; TNLG6A; TRAIL; tumor necrosis factor (ligand) family, member 10; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor apoptosis-inducing ligand splice variant delta; tumor necrosis factor ligand 6A; Tumor necrosis factor ligand superfamily member 10; tumor necrosis factor superfamily member 10